Compare BridgeBio Pharma Inc (BBIO) vs Yum China Holdings Inc (YUMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Yum China Holdings Inc — how do they compare? BridgeBio Pharma Inc trades at $83.09 (market cap $16.36B), while Yum China Holdings Inc trades at $47.57 (market cap $16.28B). The key difference: BridgeBio Pharma Inc and Yum China Holdings Inc are close in size by market cap, and Yum China Holdings Inc pays a 2.44% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | YUMC | |
|---|---|---|
Market Cap | $16.36B | $16.28B |
Sector | Health | Consumer Cyclical |
52-Week High | $90.17 | $57.95 |
52-Week Low | $47.29 | $40.18 |
Enterprise Value | $18.14B | $17.19B |
Dividend Yield | — | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.67, up 0.22% today, with a bullish technical signal and strong analyst consensus. Despite missing Q2 2026 EPS estimates with a loss of $0.78 per share, revenue beat expectations as Attruby sales surged 311% year-over-year. The company maintains a high gross margin of 94.44% but reports negative net income and cash flow from operations, reflecting its growth investment phase.
The outlook is optimistic due to multiple late-stage pipeline catalysts, including three potential product launches by mid-2027 and an FDA decision on encaleret by May 2027. Risks include sustained cash burn, high debt of $1.72 billion, and clinical trial execution. The consensus price target of $104.56 implies significant upside if commercial execution succeeds.
YUMC trades at $48.19, up 0.98% today, with a bullish technical signal from moving averages and strong earnings beats in recent quarters. The company reported revenue of $11.80B in 2025 with a net income margin of 7.84%, and recently completed the acquisition of the Pizza Hut brand in Mainland China, enhancing strategic control. Analyst consensus is strongly positive with 14 buy ratings and a projected 26.21% upside potential.
The outlook for YUMC is favorable due to consistent earnings growth, store expansion, and the Pizza Hut acquisition eliminating royalty fees. Risks include macroeconomic headwinds in China and competitive pressures. Wall Street sentiment remains bullish, supported by institutional confidence and positive earnings momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Yum China Holdings Inc
With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →
